Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
- PMID: 32065348
- PMCID: PMC7088641
- DOI: 10.1007/s11655-020-3192-6
Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
Abstract
Objective: Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed ancient classics and human studies.
Methods: Historical records on prevention and treatment of infections in CM classics, clinical evidence of CM on the prevention of severe acute respiratory syndrome (SARS) and H1N1 influenza, and CM prevention programs issued by health authorities in China since the COVID-19 outbreak were retrieved from different databases and websites till 12 February, 2020. Research evidence included data from clinical trials, cohort or other population studies using CM for preventing contagious respiratory virus diseases.
Results: The use of CM to prevent epidemics of infectious diseases was traced back to ancient Chinese practice cited in Huangdi's Internal Classic (Huang Di Nei Jing) where preventive effects were recorded. There were 3 studies using CM for prevention of SARS and 4 studies for H1N1 influenza. None of the participants who took CM contracted SARS in the 3 studies. The infection rate of H1N1 influenza in the CM group was significantly lower than the non-CM group (relative risk 0.36, 95% confidence interval 0.24-0.52; n=4). For prevention of COVID-19, 23 provinces in China issued CM programs. The main principles of CM use were to tonify qi to protect from external pathogens, disperse wind and discharge heat, and resolve dampness. The most frequently used herbs included Radix astragali (Huangqi), Radix glycyrrhizae (Gancao), Radix saposhnikoviae (Fangfeng), Rhizoma Atractylodis Macrocephalae (Baizhu), Lonicerae Japonicae Flos (Jinyinhua), and Fructus forsythia (Lianqiao).
Conclusions: Based on historical records and human evidence of SARS and H1N1 influenza prevention, Chinese herbal formula could be an alternative approach for prevention of COVID-19 in high-risk population. Prospective, rigorous population studies are warranted to confirm the potential preventive effect of CM.
Keywords: Chinese medicine; clinical evidence; corona virus disease 2019 (COVID-19); prevention program; review.
Conflict of interest statement
The authors declare that they have no competing interest.
Similar articles
-
How Chinese Herbal Medicine Prevents Epidemics: From Ancient Pestilences to COVID-19 Pandemic.Am J Chin Med. 2021;49(5):1017-1044. doi: 10.1142/S0192415X2150049X. Epub 2021 Jun 5. Am J Chin Med. 2021. PMID: 34107860 Review.
-
[Analysis of medication regularity and pharmacodynamic characteristics of traditional Chinese medicine treatment in 444 severe cases of COVID-19].Zhongguo Zhong Yao Za Zhi. 2020 Jul;45(13):3007-3012. doi: 10.19540/j.cnki.cjcmm.20200427.501. Zhongguo Zhong Yao Za Zhi. 2020. PMID: 32726005 Chinese.
-
[Medication law and mechanism of traditional Chinese medicine in prevention and treatment of epidemic diseases: based on traditional Chinese medicine theory of cold pestilence].Zhongguo Zhong Yao Za Zhi. 2022 Sep;47(17):4765-4777. doi: 10.19540/j.cnki.cjcmm.20220528.501. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 36164884 Chinese.
-
Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.J Ethnopharmacol. 2020 Aug 10;258:112932. doi: 10.1016/j.jep.2020.112932. Epub 2020 May 4. J Ethnopharmacol. 2020. PMID: 32376368 Free PMC article.
-
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.Int J Biol Sci. 2020 Mar 15;16(10):1708-1717. doi: 10.7150/ijbs.45538. eCollection 2020. Int J Biol Sci. 2020. PMID: 32226288 Free PMC article. Review.
Cited by
-
Comparative clinical trial of Langenlianqiao oral liquid and Lianhuaqingwen capsule in the treatment of mild cases of coronavirus disease 2019 (COVID-19).J Health Popul Nutr. 2024 Oct 12;43(1):158. doi: 10.1186/s41043-024-00649-6. J Health Popul Nutr. 2024. PMID: 39396047 Free PMC article. Clinical Trial.
-
Parents' Knowledge and Attitudes Regarding COVID-19: Evidence From a Tertiary Healthcare Center in Irbid, Jordan.Cureus. 2024 Jul 20;16(7):e64967. doi: 10.7759/cureus.64967. eCollection 2024 Jul. Cureus. 2024. PMID: 39161521 Free PMC article.
-
Effect of Fu Zheng Jie Du Formula on outcomes in patients with severe pneumonia receiving prone ventilation: a retrospective cohort study.Front Pharmacol. 2024 Jul 24;15:1428817. doi: 10.3389/fphar.2024.1428817. eCollection 2024. Front Pharmacol. 2024. PMID: 39114366 Free PMC article.
-
Ayurvedic and Chinese Herbs against Coronaviruses.Curr Pharm Des. 2024;30(21):1681-1698. doi: 10.2174/0113816128269864231112094917. Curr Pharm Des. 2024. PMID: 38685809 Review.
-
Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review.Food Sci Hum Wellness. 2022 Sep;11(5):1134-1142. doi: 10.1016/j.fshw.2022.04.005. Epub 2022 Jun 2. Food Sci Hum Wellness. 2022. PMID: 38621001 Free PMC article. Review.
References
-
- National Health Commission of the People’s Republic of China. Feb 12: Daily briefing on novel coronavirus cases in China. 2020.
-
- World Health Organization. Novel coronavirus (2019-nCoV) situation report 22. 2020.
-
- National Health Commission of the People’s Republic of China. Announcement of the National Health Commission of the People’s Republic of China (No. 1 in 2020). 2020/1/20. 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous